Prosonix to Present Results of Phase 2 Clinical Study of PSX1002 in COPD
Prosonix reported earlier this year that the randomised trial met its primary endpoint of demonstrating that PSX1002 improved lung function in COPD patients for a range of doses of PSX1002, compared to placebo. PSX1002 is a novel, particle-engineered, drug-only suspension formulation of glycopyrronium bromide (GB), a long-acting muscarinic antagonist (LAMA), which is in development by Prosonix as a potential 'best-in-class', once-daily, orally inhaled monotherapy for COPD in pressurised metered dose inhaler (pMDI).
Analysis of the primary endpoint (mean adjusted FEV1 AUC0-24h post dose) demonstrated statistically significant separation from placebo for all doses, with a clear progression of effect by dose. Good tolerability and safety profiles were observed for all doses of PSX1002 investigated. Multiple secondary physiological and pharmacokinetic endpoints were also met.
The positive results from this study support further clinical development of a once-daily presentation of GB in pMDI for COPD. As a proof of principle study, the results also support development of other mono and combination formulations for pMDI products using Prosonix' proprietary technology
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.